Subclinical persistence of residual acral melanoma in situ after treatment with topical imiquimod and retinoid creams
-
Published:2024-03
Issue:
Volume:45
Page:41-43
-
ISSN:2352-5126
-
Container-title:JAAD Case Reports
-
language:en
-
Short-container-title:JAAD Case Reports
Author:
Ingrassia Jenne P.,
Greenwald Elizabeth,
Meehan Shane,
Stein Jennifer A.ORCID,
Liebman Tracey N.
Reference5 articles.
1. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells;Savarese;Clin Exp Dermatol,2015
2. Use of imiquimod for residual acral melanoma;Sue;BMJ Case Rep,2014
3. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions;Hyde;Arch Dermatol,2012
4. Guidelines of care for the management of primary cutaneous melanoma;Swetter;J Am Acad Dermatol,2019
5. Treatment of lentigo maligna with imiquimod before staged excision;Cotter;Dermatol Surg,2008